Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) posted its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. Lineage Cell Therapeutics had a negative return on equity of 89.36% and a negative net margin of 434.44%.The business had revenue of $1.73 million during the quarter, compared to analysts’ expectations of $3.60 million.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Management said OpRegen remains on track in a partner-run open-label GA study, citing expanded site activations and Roche/Genentech language describing the program as potentially disease-modifying. They also highlighted long-term data showing vision gains persisted for at least three years after a single dose in the target location.
• The company emphasized major progress at its AlloSCOPE manufacturing platform, which now supports multiple new programs and could enable low-cost, scalable cell production. Management said this platform is a key differentiator because it focuses on reproducible manufacturing before clinical testing.
• COR1, Lineage’s wholly owned corneal endothelial cell program, advanced into preclinical development after the team successfully manufactured off-the-shelf cells meeting internal identity, morphology, and function criteria. Management plans to move the program into translational studies and then initial human testing.
• The ILT1 diabetes initiative is progressing through scale-up work for undifferentiated pluripotent cells, with management reporting the first internal manufacturing milestone was met. The company stressed that the main risk is proving large-scale manufacturing and differentiation can work reliably, and that this remains a stepwise go/no-go process.
• ReSonance reached an important manufacturing milestone with three successful engineering runs and a new deafening model to support functional testing. Lineage also said its Demant partnership is progressing well and that it expects to move toward GMP material and eventual FDA discussions for human testing.
• Financially, Lineage ended the quarter with $53.4 million in cash, which it says funds operations into Q2 2028. First-quarter revenue rose to $1.7 million, while operating expenses increased to $9.3 million, contributing to a net loss of $4.8 million.

Lineage Cell Therapeutics Stock Down 0.8%

Shares of Lineage Cell Therapeutics stock traded down $0.01 during trading on Friday, hitting $1.27. 1,017,805 shares of the stock traded hands, compared to its average volume of 1,172,567. The stock has a market cap of $316.61 million, a price-to-earnings ratio of -4.38 and a beta of 1.53. Lineage Cell Therapeutics has a 52 week low of $0.69 and a 52 week high of $2.09. The firm’s fifty day moving average is $1.41 and its 200-day moving average is $1.59.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LCTX. Royal Bank of Canada raised its stake in shares of Lineage Cell Therapeutics by 1,578.9% during the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock worth $237,000 after acquiring an additional 497,168 shares in the last quarter. Rhumbline Advisers grew its position in Lineage Cell Therapeutics by 9.9% during the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock worth $91,000 after acquiring an additional 18,092 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Lineage Cell Therapeutics by 117.8% in the second quarter. XTX Topco Ltd now owns 94,054 shares of the company’s stock worth $85,000 after buying an additional 50,876 shares during the period. Jump Financial LLC bought a new position in shares of Lineage Cell Therapeutics during the second quarter valued at about $28,000. Finally, WINTON GROUP Ltd purchased a new stake in Lineage Cell Therapeutics in the 2nd quarter worth approximately $69,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LCTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 24th. B. Riley Financial boosted their target price on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price target on shares of Lineage Cell Therapeutics in a report on Monday, May 4th. Finally, Canaccord Genuity Group started coverage on Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They set a “buy” rating and a $9.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $6.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.